AR035079A1 - Uso de un inhibidor de la interaccion cd2/lfa-3 - Google Patents
Uso de un inhibidor de la interaccion cd2/lfa-3Info
- Publication number
- AR035079A1 AR035079A1 ARP020100293A ARP020100293A AR035079A1 AR 035079 A1 AR035079 A1 AR 035079A1 AR P020100293 A ARP020100293 A AR P020100293A AR P020100293 A ARP020100293 A AR P020100293A AR 035079 A1 AR035079 A1 AR 035079A1
- Authority
- AR
- Argentina
- Prior art keywords
- lfa
- inhibitor
- fragment
- interaction inhibitor
- disorder
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 4
- 108010084313 CD58 Antigens Proteins 0.000 title abstract 3
- 230000003993 interaction Effects 0.000 title abstract 2
- 239000012634 fragment Substances 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 102000004127 Cytokines Human genes 0.000 abstract 1
- 108090000695 Cytokines Proteins 0.000 abstract 1
- 108060003951 Immunoglobulin Proteins 0.000 abstract 1
- 102000008070 Interferon-gamma Human genes 0.000 abstract 1
- 108010074328 Interferon-gamma Proteins 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 230000001594 aberrant effect Effects 0.000 abstract 1
- NUZWLKWWNNJHPT-UHFFFAOYSA-N anthralin Chemical compound C1C2=CC=CC(O)=C2C(=O)C2=C1C=CC=C2O NUZWLKWWNNJHPT-UHFFFAOYSA-N 0.000 abstract 1
- 239000012752 auxiliary agent Substances 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 208000037976 chronic inflammation Diseases 0.000 abstract 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 229960002311 dithranol Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000002500 effect on skin Effects 0.000 abstract 1
- 102000018358 immunoglobulin Human genes 0.000 abstract 1
- 229960003130 interferon gamma Drugs 0.000 abstract 1
- 150000007931 macrolactones Chemical class 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
- 238000001959 radiotherapy Methods 0.000 abstract 1
- 150000003431 steroids Chemical class 0.000 abstract 1
- 230000000699 topical effect Effects 0.000 abstract 1
- 239000011782 vitamin Substances 0.000 abstract 1
- 229940088594 vitamin Drugs 0.000 abstract 1
- 229930003231 vitamin Natural products 0.000 abstract 1
- 235000013343 vitamin Nutrition 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2824—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD58
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Uso de un inhibidor de la interacción CD2/LFA-3, por ejemplo un fragmento de adhesión a CD2 de LFA-3 fusionado con una inmunoglobulina o con un fragmento de la misma para la manufactura de un medicamento para tratar o prevenir en un sujeto un desórden epidérmico o dérmico caracterizado por la proliferación o actividad aberrante de células T, como por ejemplo psoriasis, desórden autoinmune y desórden inflamatorio crónico. Dicho inhibidor puede utilizarse en combinación con un agente auxiliar, como terapia de radiación, inhibidores de citoquinas, agentes de adhesión a interferón gamma, etc. Su uso puede comprender además aplicaciones tópicas de esteroides, vitaminas, alquitrán, antralina y/o macrolactonas.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26596401P | 2001-02-01 | 2001-02-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR035079A1 true AR035079A1 (es) | 2004-04-14 |
Family
ID=23012611
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP020100293A AR035079A1 (es) | 2001-02-01 | 2002-01-28 | Uso de un inhibidor de la interaccion cd2/lfa-3 |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US20040170635A1 (es) |
| EP (1) | EP1409015A4 (es) |
| JP (1) | JP2004527477A (es) |
| KR (1) | KR20040043112A (es) |
| CN (1) | CN1527723A (es) |
| AR (1) | AR035079A1 (es) |
| BG (1) | BG108020A (es) |
| BR (1) | BR0206905A (es) |
| CA (1) | CA2436411A1 (es) |
| CZ (1) | CZ20032081A3 (es) |
| EA (1) | EA200300849A1 (es) |
| EE (1) | EE200300366A (es) |
| GE (1) | GEP20063828B (es) |
| HU (1) | HUP0303826A2 (es) |
| IS (1) | IS6894A (es) |
| MX (1) | MXPA03006919A (es) |
| NO (1) | NO20033443L (es) |
| PL (1) | PL368556A1 (es) |
| SK (1) | SK9722003A3 (es) |
| WO (1) | WO2002060480A1 (es) |
| YU (1) | YU61203A (es) |
| ZA (1) | ZA200305936B (es) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6764681B2 (en) | 1991-10-07 | 2004-07-20 | Biogen, Inc. | Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction |
| HUP0103563A3 (en) * | 1998-08-31 | 2004-04-28 | Biogen Idec Ma Inc Cambridge | Method of modulating memory effector t-cells and compositions |
| AU2002250236A1 (en) * | 2001-03-02 | 2002-09-19 | Medimmune, Inc. | Cd2 antagonists for treatment of autoimmune or inflammatory disease |
| CA2454618C (en) | 2001-07-24 | 2012-04-03 | Biogen Idec Ma, Inc. | Methods for treating or preventing sclerotic disorders using cd2-binding agents |
| EP1556020B1 (en) | 2002-08-12 | 2009-02-25 | Actavis Group hf. | Use of cgrp antagonist compounds for treatment of psoriasis |
| GB0307864D0 (en) * | 2003-04-04 | 2003-05-14 | Novartis Ag | Pharmaceutical composition |
| CA2555144A1 (en) * | 2004-02-06 | 2005-08-25 | Astellas Us Llc | Methods of treating skin disorders |
| EP1747291A2 (en) * | 2004-05-04 | 2007-01-31 | Genaissance Pharmaceuticals, Inc. | Haplotype markers and methods of using the same to determine response to treatment |
| WO2005115436A1 (en) * | 2004-05-07 | 2005-12-08 | Astellas Us Llc | Soluble lfa-3 polypeptide for treating viral disorders |
| US20060078580A1 (en) * | 2004-10-08 | 2006-04-13 | Mediquest Therapeutics, Inc. | Organo-gel formulations for therapeutic applications |
| CN101113459A (zh) * | 2007-07-16 | 2008-01-30 | 东莞太力生物工程有限公司 | 一种重组复制缺陷型病毒、含有该病毒的药物组合物及其应用 |
| WO2011031676A2 (en) | 2009-09-10 | 2011-03-17 | Mayo Foundation For Medical Education And Research | Depleting immunosuppressive monocytes within a mammal |
| US9266957B2 (en) | 2009-11-10 | 2016-02-23 | Mayo Foundation For Medical Education And Research | Methods and materials for treating renal cell carcinoma and glioblastoma multiforme |
| WO2014025198A2 (ko) * | 2012-08-09 | 2014-02-13 | 주식회사 한독 | Lfa3 변이체 및 상기 변이체 또는 lfa3 cd2 결합영역과 이에 표적 특이적 폴리펩타이드가 연결된 융합단백질 및 그 용도 |
| WO2014078272A1 (en) | 2012-11-13 | 2014-05-22 | Mayo Foundation For Medical Education And Research | Methods and materials for assessing immune system profiles |
| US10094835B2 (en) | 2013-05-09 | 2018-10-09 | Mayo Foundation For Medical Education And Research | Treating patients based on immune subtypes |
| US11433119B2 (en) | 2016-11-18 | 2022-09-06 | Nepsone Ehf | Methods of treating inflammatory skin disorders |
| WO2023224980A1 (en) * | 2022-05-17 | 2023-11-23 | The Uab Research Foundation | Methods and compositions for treating or preventing inflammatory skin disorders |
| WO2024050455A2 (en) * | 2022-08-31 | 2024-03-07 | Heitmeyer Jamie Nicole | Anti-rhd antibodies for treating inflammatory dermal condition |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6162432A (en) * | 1991-10-07 | 2000-12-19 | Biogen, Inc. | Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction |
| EP0607332B1 (en) * | 1991-10-07 | 1997-12-17 | Biogen, Inc. | Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the cd2/lfa-3 interaction |
| US6764681B2 (en) * | 1991-10-07 | 2004-07-20 | Biogen, Inc. | Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction |
| US5817311A (en) * | 1993-03-05 | 1998-10-06 | Universite Catholique De Louvain | Methods of inhibiting T-cell medicated immune responses with LO-CD2a-specific antibodies |
| US5951983A (en) * | 1993-03-05 | 1999-09-14 | Universite Catholique De Louvain | Methods of inhibiting T cell mediated immune responses with humanized LO-CD2A-specific antibodies |
| US5730979A (en) * | 1993-03-05 | 1998-03-24 | Universite Catholique Delouvain | LO-CD2a antibody and uses thereof for inhibiting T cell activation and proliferation |
| HUP0103563A3 (en) * | 1998-08-31 | 2004-04-28 | Biogen Idec Ma Inc Cambridge | Method of modulating memory effector t-cells and compositions |
-
2002
- 2002-01-25 JP JP2002560671A patent/JP2004527477A/ja not_active Withdrawn
- 2002-01-25 EA EA200300849A patent/EA200300849A1/ru unknown
- 2002-01-25 EE EEP200300366A patent/EE200300366A/xx unknown
- 2002-01-25 CN CNA028079191A patent/CN1527723A/zh active Pending
- 2002-01-25 MX MXPA03006919A patent/MXPA03006919A/es unknown
- 2002-01-25 WO PCT/US2002/002314 patent/WO2002060480A1/en not_active Application Discontinuation
- 2002-01-25 KR KR10-2003-7010218A patent/KR20040043112A/ko not_active Application Discontinuation
- 2002-01-25 YU YU61203A patent/YU61203A/sh unknown
- 2002-01-25 SK SK972-2003A patent/SK9722003A3/sk unknown
- 2002-01-25 CA CA002436411A patent/CA2436411A1/en not_active Abandoned
- 2002-01-25 EP EP02704253A patent/EP1409015A4/en not_active Withdrawn
- 2002-01-25 BR BR0206905-9A patent/BR0206905A/pt not_active Application Discontinuation
- 2002-01-25 GE GE5273A patent/GEP20063828B/en unknown
- 2002-01-25 HU HU0303826A patent/HUP0303826A2/hu unknown
- 2002-01-25 CZ CZ20032081A patent/CZ20032081A3/cs unknown
- 2002-01-25 PL PL02368556A patent/PL368556A1/xx not_active Application Discontinuation
- 2002-01-25 US US10/470,764 patent/US20040170635A1/en not_active Abandoned
- 2002-01-28 AR ARP020100293A patent/AR035079A1/es unknown
- 2002-12-26 US US10/329,599 patent/US20030185824A1/en not_active Abandoned
-
2003
- 2003-07-22 BG BG108020A patent/BG108020A/bg unknown
- 2003-07-25 IS IS6894A patent/IS6894A/is unknown
- 2003-07-31 ZA ZA2003/05936A patent/ZA200305936B/en unknown
- 2003-08-01 NO NO20033443A patent/NO20033443L/no unknown
-
2005
- 2005-12-20 US US11/312,627 patent/US20070031443A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EA200300849A1 (ru) | 2004-02-26 |
| EP1409015A4 (en) | 2006-04-12 |
| EP1409015A1 (en) | 2004-04-21 |
| ZA200305936B (en) | 2005-01-26 |
| IS6894A (is) | 2003-07-25 |
| CZ20032081A3 (cs) | 2004-01-14 |
| US20070031443A1 (en) | 2007-02-08 |
| JP2004527477A (ja) | 2004-09-09 |
| BR0206905A (pt) | 2004-07-06 |
| KR20040043112A (ko) | 2004-05-22 |
| MXPA03006919A (es) | 2004-06-02 |
| CA2436411A1 (en) | 2002-08-08 |
| US20040170635A1 (en) | 2004-09-02 |
| NO20033443L (no) | 2003-09-30 |
| US20030185824A1 (en) | 2003-10-02 |
| NO20033443D0 (no) | 2003-08-01 |
| YU61203A (sh) | 2006-05-25 |
| GEP20063828B (en) | 2006-05-10 |
| EE200300366A (et) | 2003-12-15 |
| SK9722003A3 (en) | 2004-05-04 |
| PL368556A1 (en) | 2005-04-04 |
| WO2002060480A1 (en) | 2002-08-08 |
| WO2002060480A9 (en) | 2004-05-27 |
| BG108020A (bg) | 2004-03-31 |
| HUP0303826A2 (hu) | 2004-03-01 |
| CN1527723A (zh) | 2004-09-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR035079A1 (es) | Uso de un inhibidor de la interaccion cd2/lfa-3 | |
| ECSP056132A (es) | Combinaciones para el tratamiento de enfermedades que implican proliferación, migración o apoptosis celulares de células de mieloma, o angiogénesis | |
| BR9307646A (pt) | Pirrolopirimidinas como antagonistas de crf | |
| DK2455083T3 (da) | Farmaceutisk sammensætning til dermal anvendelse omfattende calcipotriol og betamethason til behandling af psoriasis | |
| BR0109705A (pt) | Uso combinado de anticorpos ou antagonistas anti-citocina e anticd20 para o tratamento de linfoma de célula b | |
| DK1071417T3 (da) | Anvendelse af cannabidiol som anti-inflammatorisk middel | |
| DK1173252T3 (da) | Produkter og fremgangsmåder til brachyterapi | |
| IS2902B (is) | Notkun á CGRP mótlyfsefnasamböndum fyrir meðhöndlun á sóra | |
| DE69522012T2 (de) | Karzinombehandlung | |
| DE60017878D1 (de) | Kombinationspräparate zur behandlung von erkrankungen, die mit angiogenese verbunden sind | |
| ES2089687T3 (es) | 4-fenil-piridonas y 4-fenil-2-alcoxipiridinas sustituidas como inhibidores de la hmg-coa-reductasa. | |
| GT199800171A (es) | Inhibidores selectivos directos o indirectos del factor xa. | |
| MXPA05010402A (es) | Oxido nitrico en el tratamiento de la inflamacion. | |
| AU2001234273A1 (en) | Thiazolopyrimidines and their use as modulators of chemokine receptor activity | |
| CA2163118A1 (en) | Aurintricaboxylic Acid Fractions and Analogues with Anti-Angiogenic Activity and Methods of Use | |
| ES2174533T3 (es) | Uso de una mezcla de un diol y un acido alfa-hidroxi para el tratamiento de enfermedades de la piel hiperqueratoticas. | |
| DE69633396D1 (de) | Activin stimulator enthaltende pharmazeutische zusammensetzung | |
| PT971710E (pt) | Utilizacao de queleritrina e radiacao para terapia de tumores | |
| AU3908997A (en) | Treatment of stress-induced skin disease by corticotropin releasing hormone antagonists and skin mast cell degranulation inhibitors | |
| ES2187799T3 (es) | Complejos de bis-platino con derivados de polimetileno como ligandos que tienen actividad antitumoral. | |
| ES2194104T3 (es) | Uso de selegilina para el tratamiento de la perdida de audicion en mamiferos. | |
| ES2181915T3 (es) | Ctla-8 en combinacionpn con g-csf y il-6, y uso de ctla-8 para tratar infecciones. | |
| ES2139729T3 (es) | Uso del factor xiii aplicado topicamente para la inhibicion de hemorragias. | |
| MX9707939A (es) | Uso de antagonistas del factor inhibidor de la leucemia y la endotelina. | |
| TR199700409T1 (xx) | Harici kullan�ma mahsus enflamasyon �nleyici madde. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |